retatrutide efficacy clinical trials A new trial from Eli Lilly and Company suggests its experimental triple hormone drug, retatrutide, could become one of the next major medications in the rapidly growing weight loss and diabetes ESC 2024: Retatrutide improves lipid

Industry analysts expect a potential approval window around 2026 to 2027, pending trial results and regulatory review

Evans M, McEwan P, O'Shea R, George L

Trifecta's food has the following benefits: Tailored for GLP-1 needs : Whole foods, whole grains, high fiber, non-starch vegetables, cooked in olive or avocado oil, and high-quality proteins

Safety and Side Effect Profile Both compounds belong to the same general drug class and share a broadly similar side effect profile, largely gastrointestinal in nature

Table of Contents: What are GLP-1 medications

It has a specific pharmacological cause that sets retatrutide apart from every other approved or investigational GLP-1 medication including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound)